Dr Ivy Mwangi‘s…thoughts are on a court case…in India [that] pit[s]…Novartis…against an Indian patent system that it says stifles innovation...Health campaigners fear stronger patent laws enacted by India in 2005…will jeopardise India's role as a source of cheap generic medicines for the most needy…Novartis…points out that safeguards already exist in international trade agreements. These protect access to essential medicines by allowing for the export of drugs which are produced under compulsory licenses...Novartis…wants patent protection in markets where patients are able to pay…But Mwangi [says] "The access programmes and safeguards in place don't allow…the number of drugs [needed]"…